TD Cowen analyst Dan Brennan raised the firm’s price target on Natera to $110 from $87 and keeps an Outperform rating on the shares. The firm said the company’s strong results and outlook supports their positive thesis.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on NTRA:
- Natera announces next phase of CareDx patent infringement litigation
- Canaccord bullish on Natera growth potential as Medicare extends coverage
- Medicare extends coverage of Natera’s signatera MRD test to ovarian cancer
- NTRA Earnings this Week: How Will it Perform?
- Natera downgraded to Outperform from Strong Buy at Raymond James
